Prescription Digital Therapeutics (PDTs) and Software-Enhanced (SE) Drugs
Medidata and Click Therapeutics advance software as prescription medical treatments
This industry-leading partnership between Medidata and Click Therapeutics advances software as prescription medical treatments — not just in clinical trials, but across the entire patient journey, from study participation to ongoing care.
Together, this partnership creates the first end-to-end offering that unifies clinical research and patient-centric therapeutic design to support the development of Prescription Digital Therapeutics (PDTs) and Software-Enhanced (SE) drugs, setting a new gold standard in patient-centric care.
Learn how to open new pipelines of opportunity and diversify your portfolio while driving better patient experiences and outcomes.
Advancing Novel Digital Treatments with the Medidata & Click Therapeutics Partnership
Learn more about how this partnership can open new pipelines of opportunity and drive meaningful advancements in patient care with digital interventions developed and validated through Click’s scientific rigor and Medidata’s clinical trial platform.
Dassault Systèmes Intensifies the MEDIDATA Commitment to Patient Experience with Investment in Click Therapeutics for Digital Therapeutics beyond Clinical Trials
Improving patient engagement – post-trial through commercialization – and advancing the Patient Experience to deliver end-to-end technology solutions across the healthcare ecosystem.
5 Step to Power Your Pipeline with Digital Therapeutics
Medidata and Click Therapeutics introduce five steps to take when beginning to evaluate your drug pipeline for differentiation with digital therapeutics.
Patients, Pipeline & Promise: Software-Enhanced Drugs
Anthony Costello, Medidata’s CEO, and David Klein, Click Therapeutics Founder and CEO, and a panel of experts discuss why now is the time for you to embrace Software-Enhanced (SE) drugs.
Optimal Patient Outcomes. One Powerful Partnership
The unified expertise of Click Therapeutics and Medidata drive the discovery, development, and clinical validation of your advanced novel digital treatments.
Develop: Click Therapeutics
Deep Development Expertise
Over a decade of experience in developing clinically validated, FDA-regulated Prescription Digital Therapeutics.
Trusted Pharma Partner-of-choice
Rich history of successful partnerships with Phama in developing regulated digital treatment solutions for improved outcomes.
Validate: Medidata
Single Patient Portal
Empowers patients to join, enroll, and participate in clinical trials from anywhere on any device.
Unified platform
Streamlines end-to-end clinical trial processes and data flow at scale, from consent to data capture to reimbursement for the ultimate patient experience.
The Time is Now for Software Based Treatments
Medidata and Click Therapeutics are streamlining software-based treatments to market with confidence, backed by decades of proven success in clinical trial execution and DTx development across a wide range of therapeutic areas.
Medicine Just Got a Digital Upgrade
Combine software with pharmacotherapy to create Software-Enhanced Drug™ treatment options, targeting the unique needs of a specific medication to differentiate your portfolio and deliver added clinical benefit to patients.
Evidence-based, high-impact software as medicine.
Click’s platform can target any disease, symptom or side effect with an underlying neurological or behavioral component, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases.
Industry Insights
Where Clinical Trial Activities Meet Digital Therapeutics
With FDA guidance on Prescription Drug Use-Related Software (PDURS), now is the time to expand and enhance treatment options for patients with Digital Therapeutics.
Medidata and Click Therapeutics extend patient engagement beyond the trial, creating lifelong connections from clinical trials to continuous care using DTx.
Interested in learning more? Sign-up to be notified as more information becomes available.